---
layout: post
title: "Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability"
date: 2026-02-05 18:35:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-01467
original_published: 2023-01-25 00:00:00 +0000
significance: 8.00
---

# Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** January 25, 2023 00:00 UTC
**Document Number:** 2023-01467

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry entitled "Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act." This guidance describes FDA's regulatory and enforcement priorities regarding compounding certain ibuprofen oral suspension products in outsourcing facilities for administration in hospitals and health systems.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/01/25/2023-01467/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-of-the-federal-food-drug)
- API: https://www.federalregister.gov/api/v1/documents/2023-01467

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
